

## ALEXANDRA - IMPASSION 030 (dernière mise à jour : 01/08/2019)

[ARCHIMAIDindex.php?action=show&id=779](http://ARCHIMAIDindex.php?action=show&id=779)

### Informations générales

**Titre de l'étude** : Etude de phase III, multicentrique, randomisée, en ouvert, comparant l'atézolizumab (Anticorps anti-PDL1) en association à la chimiothérapie adjuvante à base d'anthracycline/taxane versus chimiothérapie seule chez des patients atteints d'un cancer du sein triple négatif opérable

**Traitement** : Adjuvant

**Type d'étude** : Ciblage moléculaire / Innovation thérapeutique

**Phase** : III      **Stade** : Localisé à Localement avancé      **Ligne(s)** :

**Schéma** : This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast Cancer)

2 treatment arms:

- Experimental: Atezolizumab + Chemotherapy

Participants will receive atezolizumab (in combination with chemotherapy as described below) every 2 weeks for 10 doses, followed by atezolizumab maintenance therapy every 3 weeks to complete 1 year of treatment from the first dose

Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)

- Active Comparator: Chemotherapy

Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)

### Spécialités / Localisations

**Spécialité n°1** : Seins, organes génitaux de la femme

**CIM10 - Localisation n°1** : **C50** - Tumeur maligne du sein

### Critères

**Critères d'inclusion** : - Non-metastatic operable Stage II-III breast cancer

- Histologically documented TNBC (Triple Negative Breast Cancer)

- Confirmed tumor PD-L1 evaluation as documented through central testing of a representative tumor tissue specimen

- Adequately excised: Patients must have undergone either breast-conserving surgery or mastectomy/nipple- or skin-sparing mastectomy

- Adequate hematologic and end-organ function

- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures

- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm.

- No more than 8 weeks (56 days) may elapse between definitive breast surgery and randomization.
- Representative formalin-fixed, paraffin embedded (FFPE) tumor specimen from surgical resection in paraffin blocks (preferred) or at least 25 unstained slides.

**Critères de non-inclusion :** - Prior history of invasive breast cancer

- For the currently diagnosed breast cancer, any previous systemic anti-cancer treatment (e.g., neoadjuvant or adjuvant), including, but not limited to, chemotherapy, anti-HER2 therapy.
- Previous therapy with anthracyclines or taxanes for any malignancy
- Cardiopulmonary dysfunction
- Prior malignancies within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome
- Active or history of autoimmune disease or immune deficiency
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- Urinary outflow obstruction
- Active tuberculosis
- Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment or anticipation of need for a major surgical procedure during study treatment or within 5 months following the last dose of Atezolizumab (for patients randomized to Atezolizumab)
- Prior allogeneic stem cell or solid organ transplant
- Treatment with systemic immunosuppressive medications within 2 weeks prior to initiation of study treatment or anticipation of need for systemic immunosuppressive medication during the study

## Informations promoteur

**Nom du promoteur :** HOFFMANN-LA ROCHE

**Type de promoteur :** Industriel

**Adresse :** - 00000 HORS FRANCE

**Coordonnateur :** - *Mail* : - *Tél* :

## Informations centre investigateur n°1

**Nom du centre :** Centre Henri Becquerel

**Adresse :** Rue d'Amiens CS 11516 76000 ROUEN

**Investigateur :** Jean-Christophe THERY

**TEC / ARC / IDE :** Delphine BRIDELANCE - *Mail* : delphine.bridelance@chb.unicancer.fr - *Tél* : 02.76.67.30.33

**Ouverture de l'essai :** OUVERT

## Liens utiles

**ClinicalTrials :** <https://clinicaltrials.gov/ct2/show/NCT03498716?titles=impassion&cntry=FR&rank=1>

